MedTrace Logo

Fluorine-18-α-Methyltyrosine Positron Emission Tomography (18F-FMT PET) for Therapy Response in Lung Cancer

NCT00826033 · Status: COMPLETED · Type: OBSERVATIONAL

Last updated 2009-01-21

No results posted yet for this study

Summary

L-\[3-18F\]-α-methyltyrosine (18F-FMT) is an amino-acid tracer for positron emission tomography (PET). The investigators evaluated the value of 18F-FMT PET for the assessment of therapy response in patients with lung cancer as compared with that of 2-\[18F\]-fluoro-2-deoxy-D-glucose (18F-FDG) PET.

The patients with lung cancer underwent PET studies with 18F-FDG and 18F-FMT before and after radio-/chemotherapy. The investigators used the ratio of the SUVmax of the mediastinal (N2) lymph node to the SUVmax of the primary tumor (N/P ratio ). All patients were divided into two groups of N/P ratio\<1 and N/P ratio≥1, and the survival time was estimated by Kaplan-Meier method.

Conditions

Sponsors & Collaborators

  • J~pharma

    collaborator INDUSTRY

  • Gunma University

    lead OTHER

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Japan

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00826033 on ClinicalTrials.gov